Harvard Bioscience Inc.

NASDAQ: HBIO · Real-Time Price · USD
0.45
-0.22 (-32.86%)
At close: May 30, 2025, 3:59 PM
0.45
-0.44%
After-hours: May 30, 2025, 05:57 PM EDT

Harvard Bioscience Statistics

Share Statistics

Harvard Bioscience has 44.21M shares outstanding. The number of shares has increased by 1.48% in one year.

Shares Outstanding 44.21M
Shares Change (YoY) 1.48%
Shares Change (QoQ) 1.05%
Owned by Institutions (%) 71.18%
Shares Floating n/a
Failed to Deliver (FTD) Shares 15
FTD / Avg. Volume n/a

Short Selling Information

The latest short interest is 1.96M, so 4.43% of the outstanding shares have been sold short.

Short Interest 1.96M
Short % of Shares Out 4.43%
Short % of Float 4.79%
Short Ratio (days to cover) 1.14

Valuation Ratios

The PE ratio is -7.41 and the forward PE ratio is 11.26. Harvard Bioscience's PEG ratio is -0.03.

PE Ratio -7.41
Forward PE 11.26
PS Ratio 0.98
Forward PS 0.2
PB Ratio 1.45
P/FCF Ratio -76.3
PEG Ratio -0.03
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Harvard Bioscience.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.7.

Current Ratio 0.82
Quick Ratio 0.4
Debt / Equity 0.7
Debt / EBITDA -30.19
Debt / FCF -36.96
Interest Coverage -1.94

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $285,257.58
Profits Per Employee $-37,590.91
Employee Count 330
Asset Turnover 0.74
Inventory Turnover 1.69

Taxes

Income Tax 740K
Effective Tax Rate -6.34%

Stock Price Statistics

The stock price has increased by -85.8% in the last 52 weeks. The beta is 1.45, so Harvard Bioscience's price volatility has been higher than the market average.

Beta 1.45
52-Week Price Change -85.8%
50-Day Moving Average 0.42
200-Day Moving Average 1.68
Relative Strength Index (RSI) 54.63
Average Volume (20 Days) 10,836,938

Income Statement

In the last 12 months, Harvard Bioscience had revenue of 94.14M and earned -12.4M in profits. Earnings per share was -0.28.

Revenue 94.14M
Gross Profit 54.77M
Operating Income -6.21M
Net Income -12.4M
EBITDA -1.47M
EBIT -8.46M
Earnings Per Share (EPS) -0.28
Full Income Statement

Balance Sheet

The company has 4.11M in cash and 44.49M in debt, giving a net cash position of -40.39M.

Cash & Cash Equivalents 4.11M
Total Debt 44.49M
Net Cash -40.39M
Retained Earnings -158.01M
Total Assets 79.8M
Working Capital -10.7M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.44M and capital expenditures -2.64M, giving a free cash flow of -1.2M.

Operating Cash Flow 1.44M
Capital Expenditures -2.64M
Free Cash Flow -1.2M
FCF Per Share -0.03
Full Cash Flow Statement

Margins

Gross margin is 58.18%, with operating and profit margins of -6.6% and -13.18%.

Gross Margin 58.18%
Operating Margin -6.6%
Pretax Margin -12.39%
Profit Margin -13.18%
EBITDA Margin -1.57%
EBIT Margin -6.6%
FCF Margin -1.28%

Dividends & Yields

HBIO does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for HBIO is $3, which is 566.7% higher than the current price. The consensus rating is "Hold".

Price Target $3
Price Target Difference 566.7%
Analyst Consensus Hold
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Nov 4, 2013. It was a forward split with a ratio of 1319:1000.

Last Split Date Nov 4, 2013
Split Type forward
Split Ratio 1319:1000

Scores

Altman Z-Score -4.38
Piotroski F-Score 5